Tatevik Hovakimyan: Proud to Be Part of This Important Health Economic Project
Tatevik Hovakimyan, Co-Founder and CEO at CardioLab Medical Center, reposted Philippe Timmermans’s post on LinkedIn:
“Proud to be part of this important health economic project.”
Quoting Philippe Timmermans’s post:
“If you would build your health care system from the ground up, where would you start? Which interventions would you prioritize? Or, if health care expenditure is limited, which interventions would you prefer above others?
The ESC guidelines provide us invaluable insights for clinical practice, but lack a health economical perspective. Formal health technological assessments can provide insights in cost-effectiveness of a certain intervention, but is not available for every treatment modality, is country/health care system specific and comes with an intrinsic financial cost.
Therefore, we developed a novel framework that acts as a ‘go between’, assessing both clinical impact, complexity of implementation and quantification of clinical endpoints at a fixed time interval – irrespective of health care system. Dedicated visualization of the paramaters was developed, based on the current layout of the ESC guidelines but integrating both the novel qualitative and quantitative parameters. The 2021/2023 ESC heart failure guidelines were used to deploy this novel framework. The paper of this pilot project, supported by the ESC, is published in the European Heart Journal Quality of Care and Clinical Outcomes – check it out here.
Title: Priority measures for implementation: an ESC pilot linking guidelines to practice
Authors: Philippe Timmermans, Jr, Clara E E van Ofwegen, Filip Zemrak, Janneke W C M Mulder, Fenny Shidhika, Tatevik Hovakimyan, Theresa A McDonagh, Marco Metra, Eva Prescott, Eric Boersma
It is aimed at facilitating interaction between health care professionals and health policy stakeholders. As this framework is the product of many brainstorm sessions, statistical analysis, writing and rewriting, the authors are eager to hear feedback from our peers in both the clinical, health economical and health policy field. Please do share your thoughts, comments, criticism and suggestions to further improve this new framework, which we believe can be the first step in a further integration between clinical research and health economics.
I would like to thank all co-authors for the collaboration, inspiration and opportunities to work on this seminal paper.”
Explore more posts for deeper insights into hemostasis with Hemostasis Today.
-
Apr 8, 2026, 15:21Nathan Connell: Persistent Gaps in Hemophilia A Care Despite Prophylaxis
-
Apr 8, 2026, 15:16Avril Mansfield: Why Aren’t More Stroke Patients Meeting Aerobic Exercise Guidelines?
-
Apr 8, 2026, 15:06Sarah Richardson: We Need Experts, We Need Programs and We Need Accountability in Blood Disorders Community
-
Apr 8, 2026, 15:02Heghine Khachatryan: When Bleeding Appears Without a History — Think Acquired
-
Apr 8, 2026, 14:58Nominate a Bleeding Disorders Community Hero Making a Difference – NBDF
-
Apr 8, 2026, 14:56Joffrey Feriel: Comprehensive Review of Laboratory Assays for von Willebrand Factor and Associated Disorders
-
Apr 8, 2026, 14:54Husnain Ahmad: How Aortic Stenosis Can Lead to Gastrointestinal Bleeding in Heyde Syndrome
-
Apr 8, 2026, 14:51Steven Murphy: How Much Benefit Do Statins Really Provide for Cardiovascular Prevention
-
Apr 8, 2026, 14:42Joshua Muia: The Value of Collaboration and The Importance of Exchanging Ideas Across Institutions